Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + pitavastatin (Orient Pharma Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Orient Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tonvasca is an oral fixed-dose combination of the HMG-CoA reductase inhibitor (statin) pitavastatin and the cholesterol absorption inhibitor ezetimibe. Developed by Orient Pharma, Tonvasca is approved for the treatment of primary hypercholesterolemia and mixed dyslipidemia. Pitavastatin works by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which leads to an increase in LDL receptor expression and enhanced clearance of LDL-C from the blood. Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter in the small intestine, selectively inhibiting the absorption of biliary and dietary cholesterol. Together, these complementary mechanisms of action provide a synergistic reduction in LDL-C levels with a favorable metabolic safety profile.
- Brand names
- Tonvasca
- Other names
- pitavastatin + ezetimibe同抑脂同抑脂膠囊
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)ANPEP (Aminopeptidase N)
Beyond the preview
Go deeper on ezetimibe + pitavastatin (Orient Pharma Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + pitavastatin (Orient Pharma Co., Ltd.).